BEAUTY CARE

Derma e changes name, packaging for one of its products

BY Antoinette Alexander

SIMI VALLEY, Calif. Derma e Natural Bodycare has given its Complete E Cranberry Creme product a new name and upgraded packaging to better communicate to consumers the formula’s benefits.

Formerly known as Complete E Cranberry Creme, derma e’s Advanced Vitamin E Dry Skin Therapy is infused with vitamin E and cranberry seed oil that provides omega-6 and omega-3 fatty acids. 

“This product makeover will help consumers better understand the multiple benefits of our most advanced vitamin E creme. We also hope it will improve sales of such a superior formula,” stated Linda Miles, VP, derma e Natural Bodycare.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
BEAUTY CARE

Goody expands brand with Ouchless Flex line

BY Antoinette Alexander

ATLANTA Goody, a Newell Rubbermaid business unit, is expanding its Ouchless portfolio with the launch of the new Goody Ouchless Flex line of comfort-flex hair accessories.

“At Goody we are constantly engaging with our core consumers to ensure we maintain a solid understanding of what women want for their hair, and we are dedicated to meeting both their aesthetic and performance-related hair product needs,” stated A.J. Ross, president of Newell Rubbermaid’s Beauty & Style global business unit. “Based on consumer insights, we pursued extensive research and development of comfortable and stylish hard hair accessories so women can enjoy the hairstyles they create and comfortably wear them all day.”

Goody launched Ouchless a decade ago as a line of no-metal elastics and has since expanded it to include styling tools such as combs and brushes. The addition of Flex takes the Ouchless collection into three new categories of comfortable hair fashions: pressure-free headbands, updo barrettes and claw clips. The suggested retail prices range between $2.99 and $5.99.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
BEAUTY CARE

Johnson & Johnson reports decline in Q1 earnings

BY Allison Cerra

NEW BRUNSWICK, N.J. Even the big brands are feeling the economic slump.

Johnson & Johnson announced Tuesday sales of $15 billion for the first quarter of 2009, a decrease of 7.2%, compared with the first quarter of 2008.

Operational results declined 1.2% and the negative impact of currency was 6%. Domestic sales declined 5%, while international sales declined 9.6%, reflecting operational growth of 3% and a negative currency impact of 12.6%.

Net earnings for the first quarter of 2009 were $3.5 billion, representing a decrease of 2.5%, compared with the same period in 2008. Diluted earnings per share for the first quarter of 2009 were $1.26, the same versus a year ago. The company confirmed its earnings guidance for full-year 2009 of $4.45 – $4.55 per share, which excludes the impact of special items.

“Despite challenging economic and near term business pressures, we continue to deliver solid financial results,” said William C. Weldon, chairman and CEO. “We are continuing to make strategic investments in order to bring important new products to market, positioning us well for long-term growth.”

Worldwide consumer sales of $3.7 billion for the first quarter represented a decrease of 8.7%, versus the prior year with a decline of 1% operationally and a negative impact from currency of 7.7%. Domestic sales decreased 5.1%, while international sales decreased 11.6%; which reflected an operational increase of 2.4% and a negative currency impact of 14.0%.

Listerine antiseptic mouth rinse, and skin care lines of Neutrogena and Aveeno, had strong sales performance during the quarter. Also contributing were sales from the recently completed acquisition of Dabao, the leading moisturizer in China. Sales comparisons were negatively impacted due to the initial build of inventory by the trade related to the 2008 launch of Zyrtec.

Meanwhile, worldwide pharmaceutical sales of $5.8 billion for the first quarter represented a decrease versus the prior year of 10.1% with an operational decline of 5.1% and a negative impact from currency of 5%. Domestic sales decreased 9.7%, while international sales decreased 10.7%; which reflected an operational increase of 2.8% and a negative currency impact of 13.5%.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?